The Drugs Controller General of India (DCGI) has allowed Serum Institute of India (SII) to restart its phase two and three clinical trials for Covid-19 vaccine after the pharma major submitted the recommendations of the Data Safety Monitoring Board (DSMB), UK and DSMB India and requested permission to restart enrollment in the subject clinical trial of the vaccine being developed by AstraZeneca and Oxford University.
More details at the Times of India website..
No comments:
Post a Comment